WallStreetZenWallStreetZen

NASDAQ: MGX
Metagenomi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MGX stock forecasts and price targets.

Forecast return on equity

Is MGX forecast to generate an efficient return?

Company
-33.54%
Industry
66.4%
Market
180.01%
MGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MGX forecast to generate an efficient return on assets?

Company
-24.06%
Industry
31.75%
MGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MGX earnings per share forecast

What is MGX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.84
Avg 2 year Forecast
-$1.62
Avg 3 year Forecast
-$1.20

MGX revenue forecast

What is MGX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$23.9M-5.15%
Avg 2 year Forecast
$23.0M-8.75%
Avg 3 year Forecast
$20.2M-19.87%
MGX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MGX revenue growth forecast

How is MGX forecast to perform vs Biotechnology companies and vs the US market?

Company
-6.3%
Industry
35.96%
Market
13.56%
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MGX$1.44N/AN/A
HYFT$1.16N/AN/A
ICCC$6.04N/AN/A
OKUR$4.01$27.00+573.32%Buy
NRXP$1.90$38.00+1,900.00%Strong Buy
View Top Biotech Stocks

Metagenomi Therapeutics Stock Forecast FAQ

What is MGX's earnings growth forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.19%.

Metagenomi Therapeutics's earnings in 2026 is -$87,868,000.On average, 6 Wall Street analysts forecast MGX's earnings for 2026 to be -$69,139,010, with the lowest MGX earnings forecast at -$96,963,154, and the highest MGX earnings forecast at -$53,327,101. On average, 4 Wall Street analysts forecast MGX's earnings for 2027 to be -$60,922,686, with the lowest MGX earnings forecast at -$70,049,427, and the highest MGX earnings forecast at -$44,241,743.

In 2028, MGX is forecast to generate -$45,216,115 in earnings, with the lowest earnings forecast at -$43,873,062 and the highest earnings forecast at -$47,006,852.

If you're new to stock investing, here's how to buy Metagenomi Therapeutics stock.

What is MGX's revenue growth forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's forecast annual revenue growth rate of -6.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.

Metagenomi Therapeutics's revenue in 2026 is $25,210,000.On average, 6 Wall Street analysts forecast MGX's revenue for 2026 to be $899,582,113, with the lowest MGX revenue forecast at $589,889,910, and the highest MGX revenue forecast at $1,580,062,260. On average, 6 Wall Street analysts forecast MGX's revenue for 2027 to be $865,385,052, with the lowest MGX revenue forecast at $556,708,603, and the highest MGX revenue forecast at $1,580,062,260.

In 2028, MGX is forecast to generate $759,934,706 in revenue, with the lowest revenue forecast at $737,362,388 and the highest revenue forecast at $790,031,130.

What is MGX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MGX) forecast ROA is -24.06%, which is lower than the forecast US Biotechnology industry average of 31.75%.

What is MGX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's current Earnings Per Share (EPS) is -$2.36. On average, analysts forecast that MGX's EPS will be -$1.84 for 2026, with the lowest EPS forecast at -$2.58, and the highest EPS forecast at -$1.42. On average, analysts forecast that MGX's EPS will be -$1.62 for 2027, with the lowest EPS forecast at -$1.86, and the highest EPS forecast at -$1.18. In 2028, MGX's EPS is forecast to hit -$1.20 (min: -$1.17, max: -$1.25).

What is MGX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MGX) forecast ROE is -33.54%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.